$COAG

JPMorgan initiated coverage on Hemab Therapeutics (COAG) with an overweight rating and $70 price target, citing its pipeline for bleeding disorders. The stock is currently at $29.94, 46% below its 52-week high. Analysts project significant revenue potential for its lead assets, sutacimig and HMB-002, with combined revenue estimates of $4.6 billion by 2044. Other analysts have also raised price targets, reflecting positive sentiment.

Rodman & Renshaw initiated coverage on Hemab Therapeutics (NASDAQ:COAG) with a buy rating and $56.00 price target, citing potential of sutacimig for Glanzmann thrombasthenia. The company is also developing treatments for Von Willebrand disease. Hemab has a strong balance sheet with a current ratio of 35.85. Recent phase 2 data showed promising results, leading H.C. Wainwright to raise its price target to $60.

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Direct

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Cong

Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.

Investing.com reports Friday’s market weakness, with Nasdaq down about 1% and stocks set for a weekly loss. It lists major movers including Micron Tech (MU) up 3.66%, Oracle (ORCL) up 2.7%, and Coca-Cola (KO) down 4.66% after fairlife suspends US production following a cyberattack. Other cited moves include Applied Materials (AMAT) down 4.3% and SpaceX (SPCX) down 4.07%.

Hemab Therapeutics (COAG) presented Phase 2 long-term extension data for Sutacimig at ISTH 2026, treating 34 patients with median 6.9 months exposure up to 15.9 months. The company reported an ATBR 92% reduction, manageable safety, and FDA alignment to move to Phase 3 with a weekly regimen. Wedbush reiterated Outperform and a $55 target.

Hemab Therapeutics (Nasdaq:COAG) reported Phase 2 long-term extension data for sutacimig in Glanzmann thrombasthenia and preclinical results in Factor VII deficiency at ISTH 2026. In 34 patients (median 6.9 months, up to 15.9), treated bleed rates fell, with no Grade 3+ related AEs. FDA endorsed a 0.2 mg/kg Q1 week Phase 3 plan in 2H 2026.

Biotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.

Hemab Therapeutics (NASDAQ:COAG) reported early clinical and pharmacology findings for HMB-002 in von Willebrand disease, saying a single 150 mg subcutaneous dose increased VWF and FVIII by at least 2.4-fold, supported thrombin generation, and showed mild to moderate adverse events. The company also introduced HMB-003 for heavy menstrual bleeding. COAG shares were up 6.42% to $40.47.